— Why it moved
Why PPCB Stock Went Parabolic Today — June 11, 2026
A $3M preclinical pancreatic-cancer stock ran 5x on a manufacturing-deal headline, and the Stock Pulse premarket alert caught 146% of it before the fade took two thirds back.
What moved PPCB stock
Propanc Biopharma is a $3 million preclinical pancreatic-cancer company. It said it engaged a European GMP manufacturer to produce PRP, its lead candidate, ahead of a planned Phase 1b first-in-human trial in 30 to 40 solid-tumor patients; PRP holds FDA orphan drug designation. Real news for this company — but it's trial prep, not trial data.
The mechanics
A $3M market cap gapping 107% draws every momentum algo on the street: 175 million shares traded against a 15 million float, thousands of times the 30-day average. The day had two waves — a 5:47 AM premarket spike to $6.30 that fully collapsed, then a second, bigger run after the bell.
PPCB by the numbers
The alert window
Stock Pulse flagged it premarket at 8:36 AM at $2.76, after the first wave had deflated. The top, $6.79, printed at 10:15 — 99 minutes later, up 146.1%. A real-time reader had a genuine hour-and-a-half runway, one of the biggest post-alert moves in the archive.
How PPCB's move ended
Then it spent the whole session unwinding to a $2.43 close — 11.9% under the alert and 64% off the top. Five-bagger at the high, round trip by the close; the fade was as violent as the run. Preclinical means no human efficacy data, the split-adjusted $270 high shows how much dilution came before this, and a $3M-cap company funding a clinical trial will need more paper.
The tell: when a premarket spike fully collapses and then reruns bigger after the bell, both waves are flow — and flow round-trips.